The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic

International Urology and Nephrology

Volumn 43, Issue 3, 2011, Pages 821-825

  Davies, Joseph B ^a   Crook, Martin A ^a   Wierzbicki, Anthony S ^a   Goldsmith, David J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic kidney disease; Dyslipidaemia; Proteinuria

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE FACILITY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROTEIN URINE LEVEL; PROTEINURIA; TERTIARY HEALTH CARE; URINARY EXCRETION;

ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GLOMERULAR FILTRATION RATE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PREVALENCE; PROTEINURIA;

EID: 80555125052     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9819-3     Document Type: Article

References (16)

1. K/DOQI (2002) Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-S266
2. Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038-2047 (Pubitemid 350074801)
3. National Collaborating Centre for Chronic Conditions (2008) Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary care and secondary care. National Institute for Health and Clinical Excellence Clinical guideline 73, London, UK.
4. Schaeffner E, Kurth T, Curhan G et al (2003) Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14(8):2084-2091 (Pubitemid 36909916)
5. Caldicott Committee (1997) Report on the review of patient identifiable information. Department of Health, London UK.
6. National Institute for Health and Clinical Excellence (NICE) (2008) Clinical Guideline 66. Available from: Www.nice.org.uk/Guidance/CG66
7. Levey A, Coresh J, Greene T et al (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53(4):766-772 (Pubitemid 46580250)
8. Blaustein D, Kumar R, Goyzueta J (1995) Isolated proteinuria: Diagnosis and evaluation. Prim Care Update Ob Gyns 2(6):204-206
9. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circ 106: 3143
10. Samuelsson O, Mulec H, Knight-Gibson C et al (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12(9):1908-1915 (Pubitemid 27379464)
11. Muntner P, Coresh J, Smith J et al (2000) Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58(1):293-301 (Pubitemid 30429874)
12. Fox C, Larson M, Leip E et al (2004) Predictors of newonset kidney disease in a community-based population. JAMA 291(7):844-850 (Pubitemid 38543772)
13. Manttari M, Tiula E, Alikoski T et al (1995) Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26(4):670-675
14. Coresh J (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet (in press).
15. Landray M, Baigent C, Leaper C et al (2006) The second United Kingdom heart and renal protection (UK-HARP-II) study: A randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis 47(3):385-395 (Pubitemid 43255171)
16. Baigent C, Landry M (2003) Study of heart and renal protection (SHARP). Kidney Int Suppl 84:S207-S210 (Pubitemid 36513411)